Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

NCT07465835 is registered in ClinicalTrials.gov with Electra Therapeutics Inc. as lead sponsor.

NCT NCT07465835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07465835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
Lead sponsor
Electra Therapeutics Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 17, 2026
Completion date
December 31, 2028
Enrollment
84 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

t cell malignancies